PASART 2

• Research type

  Research Study

• Full title

  Phase II clinical study of concurrent PAzopanib for non-metastatic SArcoma patients to be treated with RadioTherapy, localized in the extremities, trunk and chest wall or the head and neck region.

• IRAS ID

  189180

• Contact name

  Aisha Miah

• Contact email

  aisha.miah@rmh.nhs.uk

• Sponsor organisation

  The Netherlands Cancer Institute

• Eudract number

  2015-004134-95

• Duration of Study in the UK

  2 years, 0 months, 6 days

• Research summary

  Pre-operative radiotherapy is recommended in intermediate or high grade soft tissue sarcomas to improve local control rates. However, response rates to radiotherapy alone can be at best 80%. Pazopanib is a vascular endothelial growth factor inhibitor which in early studies has been demonstrated to be safe to combine with radiotherapy. This study is wishing to determine if combination of radiotherapy with pazopanib in the pre-operative setting can improve response rates up to 95%. Parallel exploratory studies will be performed to determine predictors of response and predictors of toxicities.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  16/WM/0363

• Date of REC Opinion

  14 Sep 2016

• REC opinion

  Further Information Favourable Opinion